Maxim analyst Jason McCarthy has decided the bulls are right when it comes to the meaningful prospects glittering ahead for Gilead Sciences (NASDAQ:GILD) in the playing field of cell therapy- especially following its savvy Kite acquisition, strengthening the biotech giant’s upper hand. Now that McCarthy has come back from a management meeting in Beijing, China he is out making a new case for why now is the time to buy shares.
Gilead’s Cell Therapy Opportunity Tempts Maxim to Join the Bullish Camp
